DK1494650T3 - Farmaceutisk formulering, der indeholder melatonin - Google Patents

Farmaceutisk formulering, der indeholder melatonin

Info

Publication number
DK1494650T3
DK1494650T3 DK03746393.2T DK03746393T DK1494650T3 DK 1494650 T3 DK1494650 T3 DK 1494650T3 DK 03746393 T DK03746393 T DK 03746393T DK 1494650 T3 DK1494650 T3 DK 1494650T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulation
formulation containing
containing melatonin
melatonin
pharmaceutical
Prior art date
Application number
DK03746393.2T
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1494650(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of DK1494650T3 publication Critical patent/DK1494650T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
DK03746393.2T 2002-04-28 2003-03-20 Farmaceutisk formulering, der indeholder melatonin DK1494650T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PCT/IL2003/000240 WO2003086352A1 (en) 2002-04-08 2003-03-20 Pharmaceutical formulation comprising melatonin

Publications (1)

Publication Number Publication Date
DK1494650T3 true DK1494650T3 (da) 2011-08-08

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03746393.2T DK1494650T3 (da) 2002-04-28 2003-03-20 Farmaceutisk formulering, der indeholder melatonin

Country Status (30)

Country Link
US (1) US20050175692A1 (da)
EP (1) EP1494650B1 (da)
JP (1) JP2005527583A (da)
KR (1) KR101000624B1 (da)
CN (1) CN100386070C (da)
AR (1) AR039232A1 (da)
AT (1) ATE507831T1 (da)
AU (1) AU2003227304B2 (da)
BR (1) BR0308762A (da)
CA (1) CA2477516C (da)
DE (1) DE60336999D1 (da)
DK (1) DK1494650T3 (da)
EA (1) EA007954B1 (da)
ES (1) ES2366116T3 (da)
GT (1) GT200300064A (da)
HK (1) HK1075616A1 (da)
HN (1) HN2003000115A (da)
IL (1) IL149377A (da)
IS (1) IS2858B (da)
MX (1) MXPA04009893A (da)
NO (1) NO332525B1 (da)
NZ (1) NZ536298A (da)
PE (1) PE20040161A1 (da)
PL (1) PL209922B1 (da)
PT (1) PT1494650E (da)
TW (1) TW200305404A (da)
UA (1) UA86924C2 (da)
UY (1) UY27753A1 (da)
WO (1) WO2003086352A1 (da)
ZA (1) ZA200407563B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技(北京)有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
AU2016426598C1 (en) * 2016-10-31 2024-02-08 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
EP0885210B2 (en) * 1996-03-08 2008-06-18 Takeda Pharmaceutical Company Limited Tricylic compounds having binding affinity for melatonin receptors, their production and use
US5849338A (en) * 1996-04-10 1998-12-15 Chronorx Llc Unit dosage forms for treatment of vasoconstriction and related conditions
JP2000514455A (ja) * 1996-07-17 2000-10-31 メルク エンド カンパニー インコーポレーテッド タキキニンアンタゴニストによるサーカディアンリズムの改変
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
AU3910700A (en) * 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
ATE507831T1 (de) 2011-05-15
EP1494650A4 (en) 2006-07-12
KR101000624B1 (ko) 2010-12-10
PL209922B1 (pl) 2011-11-30
NZ536298A (en) 2008-09-26
JP2005527583A (ja) 2005-09-15
HK1075616A1 (en) 2005-12-23
CA2477516A1 (en) 2003-10-23
IL149377A0 (en) 2009-02-11
HN2003000115A (es) 2004-04-20
ES2366116T3 (es) 2011-10-17
NO332525B1 (no) 2012-10-08
UY27753A1 (es) 2003-05-30
DE60336999D1 (de) 2011-06-16
GT200300064A (es) 2003-11-26
EA007954B1 (ru) 2007-02-27
NO20043576L (no) 2004-12-22
MXPA04009893A (es) 2005-06-17
WO2003086352A1 (en) 2003-10-23
CN1646098A (zh) 2005-07-27
AU2003227304A1 (en) 2003-10-27
PL372867A1 (en) 2005-08-08
UA86924C2 (ru) 2009-06-10
CA2477516C (en) 2012-12-11
PT1494650E (pt) 2011-08-18
EA200401331A1 (ru) 2005-04-28
PE20040161A1 (es) 2004-03-22
US20050175692A1 (en) 2005-08-11
CN100386070C (zh) 2008-05-07
IL149377A (en) 2012-10-31
IS7492A (is) 2004-10-07
IS2858B (is) 2013-12-15
KR20040101406A (ko) 2004-12-02
AU2003227304B2 (en) 2007-12-06
EP1494650B1 (en) 2011-05-04
TW200305404A (en) 2003-11-01
ZA200407563B (en) 2005-11-30
AU2003227304A2 (en) 2005-04-14
AR039232A1 (es) 2005-02-09
EP1494650A1 (en) 2005-01-12
BR0308762A (pt) 2005-01-11

Similar Documents

Publication Publication Date Title
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
PT1501534E (pt) Formulacoes farmaceuticas
DK1545662T3 (da) Lægemiddelindgivelsessystem
ATE380544T1 (de) Umhüllte feste darreichungsform
DK3536344T3 (da) Superfin formoterolformulering
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20033384D0 (no) Farmasöytisk formulering
DE602004017700D1 (de) Transmukosen verabreichung
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
DE60310919D1 (de) Dosiersystem
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
IS7571A (is) Ný lífeðlisfræðilega virk efni
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
DK1587478T3 (da) Farmaceutisk sammensætning
DK1596870T4 (da) Højdosis-ibandronatformulering
DK1463551T3 (da) Veterinærmedicinsk spröjte
DK1494650T3 (da) Farmaceutisk formulering, der indeholder melatonin
DE50311317D1 (de) Dosiereinrichtung
DE50309094D1 (de) Dosiereinrichtung
NO20034952D0 (no) Farmasöytiske forbindelser
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
ATA8202001A (de) Medikamentenapplikator
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
NO20044164L (no) Farmasoytiske sammensetninger
DK1562585T3 (da) Daglige melatonindoseringsenheder